Taiwan-listed biotech looks to expand the value of its lead oncology asset through combination rese...
TAIPEI and SHANGHAI and SAN FRANCISCO, May 26, 2026 /PRNewswire/ -- HanchorBio, Inc. (TPEx: 7827), ...
Expanding HanchorBio's data-enabled approach from molecule design to portfolio and market insight ...
Listing milestone positions HanchorBio to strengthen institutional visibility, advance itsFBDB™ pla...
First SIRPα-IgG4 Fc Fusion Protein Granted Orphan Status in Gastric Cancer TAIPEI, SHANGHAI and SAN...
Sustained execution and high-impact data across HanchorBio's next-generation immuno-oncology portfo...
SHANGHAI, TAIPEI and SAN FRANCISCO, Jan. 26, 2026 /PRNewswire/ -- HanchorBio, Inc. (TPEx: 7827), a ...
International debut underscores emerging role for macrophage checkpoint therapy in gastric cancer, ...
Early Phase 1 monotherapy data demonstrate cytopenia-sparing safety, broad pharmacologic window, an...
Late-breaking poster presentations show HCB101's favorable safety, strong receptor occupancy, and p...
HCB301 is a first-in-class tri-specific immunotherapy targeting SIRPα-CD47, PD-1/PD-L1, and TGFβ; i...
FACO 2025 presentation highlights HCB101's favorable safety, strong receptor occupancy, and confirm...
* Prestigious peer-review validates HCB101's differentiated mechanism and translational strength....
TAIPEI and SHANGHAI and SAN FRANCISCO, Oct. 21, 2025 /PRNewswire/ -- HanchorBio today announced th...
Presentations highlight HCB101's differentiated profile and introduce first preclinical data from H...
TAIPEI and SHANGHAI and SAN FRANCISCO, July 1, 2025 /PRNewswire/ -- HanchorBio Inc. (7827.TWO), a g...
Interim data on the cancer treatment shows robust potential for balancing efficacy and safety TAIP...